endpts.com·Jun 5, 2026
Fulcrum Therapeutics has laid off 48 of its 57 full-time employees, significantly downsizing the company. Meanwhile, Seres Therapeutics has extended its financial runway into 2027.
The most valuable insight for you is the news that Fulcrum Therapeutics has laid off a significant portion of its workforce, reducing its operational capacity. This development may signal potential investment risks or strategic shifts in the biotech field. Additionally, Seres extending its financial runway into 2027 could indicate a stable investment opportunity with its ongoing projects.